Joslin Diabetes Center, Inc.

Joslin Diabetes Center, Inc. is a tax-exempt nonprofit research organization based in Boston, Massachusetts, that receives federal research grants as a prime recipient, conducting basic and translational research on diabetes, metabolic disease, and related conditions across the National Institutes of Health. The center acts overwhelmingly as a grant recipient (83% of recent awards are prime grants) rather than as a federal contractor, with no federal contract vehicle presence and does not compete in set-asides.

Joslin's federal research footprint concentrates on diabetes and metabolic pathophysiology. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) funds 92 awards totaling $19.4 million in combined potential value — substantially all of the center's documented prime research funding. Recent representative work includes a $868,285 R01 project grant (CFDA 93.847, awarded August 2026) to investigate brown fat-derived lipid mediators and their role in metabolic health, a $826,321 Cooperative Agreement (U01DK143496, awarded April 2026) targeting renalase as a therapeutic strategy for early-stage Type 1 Diabetes, and a $299,666 project grant (awarded September 2025) examining insulin resistance and sex-specific molecular alterations using phosphoproteomics and CRISPR screening. The center also holds awards from the National Institute on Aging (studying cognitive decline and aging-associated metabolic dysfunction), the National Institute on Child Health and Human Development (maternal exercise and infant metabolism), the National Institute of Neurological Disorders and Stroke (in vivo gene editing in muscle), and the National Institute for Minority Health and Health Disparities (continuous glucose monitoring in underrepresented populations). Work spans Type 1 and Type 2 Diabetes, obesity, cardiovascular disease, kidney disease, and neurological complications of diabetes.

Customer concentration is extreme: NIDDK accounts for 84% of awards by count, with 77 additional NIH awards across other institutes and centers representing subsidiary volume. The Indian Health Service placed 2 awards totaling $5.7 million. Performance occurs primarily at Joslin's Boston headquarters, with collaborative work routed through sub-awards to academic medical centers and research institutes including the University of Massachusetts Medical School, the Broad Institute, Case Western Reserve University, Beth Israel Deaconess Medical Center, the University of Connecticut Health Center, and Stanford University. Joslin serves as prime recipient on 193 awards and sub-recipient on 40 awards, including clinical trial site participation and collaborative research contributions to multi-center consortia.

Activity has grown over the past five years — nine awards in 2022 to twenty in 2024 — with an aggregate obligated value of $555.7 million across all awards (1,845% of the stated $30.1 million combined potential value), reflecting substantial multi-year funding flows. Twenty-three awards face ultimate completion within the next twenty-four months, creating recompete demand in diabetes research programming. Joslin competes in full-and-open federal grant mechanisms; the vendor has no SBA designations, set-asides, or contract vehicle seats. The organization operates as a research institution that uses federal dollars to conduct investigator-initiated and collaborative diabetes-focused science rather than as a service provider to federal agencies.